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ABSTRACT
Human health and ecological risk assessors are currently facing increased demands and
public pressure to evaluate the potential risk of hundreds to thousands of chemicals based
on limited toxicity data. Therefore, scientifically sound models are needed to predict
toxicity without sole reliance on conventional whole-organism (vertebrate) bioassays. To
help address this challenge, adverse outcome pathways (AOPs) have recently been
proposed as conceptual tools to help link direct, molecular-level initiating events to
adverse outcomes at higher levels of biological organization. Additionally, using AOPs
as frameworks, high-throughput screening (HTS) and high-content screening (HCS)
assays have been recently proposed as key components of a tiered regulatory toxicity
testing strategy that enables screening and prioritization of chemicals for further testing
using conventional bioassays. Therefore, using zebrafish embryonic development as a
model, the overall research aims of this dissertation were to 1) rely on paraoxon – the
active metabolite of the organophosphorus (OP) insecticide parathion – as a reference
acetylcholinesterase (AChE) inhibitor to examine whether the common molecular
initiating event (AChE inhibition) was associated with adverse neurological effects at
higher levels of biological organization and 2) develop and optimize a HCS assay to
identify chemicals impacting cardiovascular function and potentially serve as a platform
for guiding AOP discovery and development. Data presented within Chapter 1 suggests
that (1) normal AChE activity is not required for secondary motoneuron development and
(2) spontaneous tail contractions at 26 hours postfertilization (hpf) are sensitive to
v

paraoxon exposure, an effect that may be independent of AChE inhibition. Data
presented within Chapter 2 suggests that, compared to existing zebrafish-based assays,
our HCS assay provides a comprehensive chemical screening and AOP discovery
platform with 1) increased sample sizes; 2) broad concentration-response format; and 3)
the ability to identify chemicals that target cardiovascular function at non-teratogenic
concentrations. Overall, this dissertation highlights the scientific and logistical challenges
in developing quantitative AOPs to support chemical screening and prioritization
strategies. Nonetheless, qualitative AOPs can play a role in identification of HTS/HCS
assays that capture key events along an AOP, and results of HTS/HCS-based chemical
screens can be used to facilitate development of current and new AOPs.
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CHAPTER 1
INTRODUCTION
1.1 INTRODUCTION TO ADVERSE OUTCOME PATHWAYS (AOPS)
Human health and ecological risk assessors are currently facing increased
demands and public pressure to evaluate the potential risk of hundreds to thousands of
chemicals based on limited toxicity data. Therefore, scientifically sound models are
needed to predict toxicity without solely relying on conventional whole-organism
(vertebrate) bioassays. To address this challenge, the Organization for Economic Cooperation and Development (OECD) recently issued a guideline on developing and
assessing adverse outcome pathways (AOPs) (OECD, 2012). AOPs have been proposed
as conceptual frameworks to link direct, molecular-level initiating events to adverse
outcomes at higher levels of biological organization (Ankley et al., 2010). The AOP
approach is based on the notion that a toxic effect results from a chemical interacting
with an initial target and that this interaction cascades into key events that ultimately
result in an adverse outcome (OECD, 2012) (Figure 1.1). These adverse outcomes must
occur at a biological level relevant to regulatory decisions (Ankley et al., 2010), and if
not, are defined as a key event (OECD, 2012). A ‘bottom-up’ approach is often applied to
develop an AOP, where the chemistry and mode of action (MOA) are initially used to
hypothesize key events and the adverse outcome (OECD, 2012). On the other hand, a
‘top-down’ approach can be utilized by assessing the adverse outcome to formulate
hypotheses about the potential MOA(s).
1

Currently, there is an effort and interest in building and annotating qualitative
AOPs, where data is gathered from the literature to predict toxicological effects across
multiple levels of biological organization. However, these linkages are difficult to
determine due to differences in dose-response characteristics among these levels. Thus,
quantitative linkages between levels of biological organization need to be established.
Using a battery of reference chemicals with known MOAs and mechanisms of toxicity
can help in developing these quantitative AOPs. Once described and annotated, AOPs
can be used to identify alternative, high-throughput predictive assays and testing
strategies that help inform risk assessments, as well as facilitate identification of
uncertainties and corresponding research gaps. Moreover, linked with computational
tools for concentration-response extrapolation across multiple levels of biological
organization, these alternative assays, once developed and validated, will likely provide
flexibility in testing based on risk-management needs while, at the same time, reduce
animal use and study costs (NRC, 2007).

1.2 THE NEED FOR HIGH-THROUGHPUT/HIGH-CONTENT SCREENING (HTS/HCS) ASSAYS
Chemical use and migration from end-use products to indoor and outdoor
environments poses a potential risk for humans and ecosystems. Due to these concerns,
whole-organism toxicity test guidelines standardized and issued by the OECD are used to
support human health and ecological risk assessments around the world. Even though
whole-organism toxicity data are not currently required for pre-market approval of
chemicals regulated under the Toxic Substances Control Act (TSCA) within the United
States (US), amendments that have been recently proposed could significantly increase
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the demand for generating toxicity data across multiple species and hundreds to
thousands of registered and new chemicals in commerce. As of today, safety information
for over 83,000 chemicals registered under the TSCA is limited and, in most cases,
unknown. Currently, the Environmental Protection Agency (EPA) uses quantitative
structure-activity relationships (QSAR) and ecologically structure-activity relationships
(ECOSAR) models to determine the hazards of these registered chemicals, and toxic
effects of a newly registered chemical are predicted by relying on structural attributes,
physicochemical properties, and potential metabolites that can be easily determined.
However, this type of testing is not always predictive when determining the potential
toxicity of each chemical. Moreover, a chemical registrant must notify the EPA of their
intention to manufacture a new chemical. The EPA then has 90 days to block the
manufacture of this chemical, or it can be legally marketed without any additional
toxicity tests. With the proposed amendments to TSCA to require toxicity tests and
continued registration and re-registration of pesticides under the Federal Insecticide,
Fungicide, and Rodenticide Act (FIFRA), there will likely be a significant increase in
demand to use whole-organism guideline toxicity tests. These guideline tests are not only
costly and animal-intensive, but also provide minimal information about chemical MOA
due to a principal focus on apical endpoints such as survival, development, and
reproduction.
Around the world, there is an intense effort and vested interest in reducing animal
usage. European countries have taken the lead on this effort, and the Registration,
Evaluation, Authorization, and Restriction of Chemical Substances (REACH) regulation
was implemented within Europe in June of 2007 with the aim to “improve the protection
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of human health and the environment through the better and earlier identification of the
intrinsic properties of chemical substances” (REACH, 2010). Similar to the EPA,
chemical manufacturers are required to collect and submit safety data for evaluation by
regulatory authorities; furthermore, REACH requires that these data be shared among
registrants to avoid unnecessary animal testing (REACH, 2010). One goal of REACH is
to replace, reduce, and refine the use of animals in scientific procedures, thus a
replacement to whole-animal testing must always be considered first. When an
alternative is not possible, reduction alternatives (fewer animals are used) and refinement
alternatives (methods that cause the least pain and suffering) are used (REACH, 2010).
Therefore, due to the limitations of whole-organism toxicity tests and the interest in
reducing animal usage, resource-efficient alternatives such as high-throughput and highcontent screening assays have been proposed as key components of a future testing
strategy for regulatory toxicology and ecotoxicology (Andersen and Krewski, 2009;
Bradbury et al., 2004; NRC, 2007; Villeneuve and Garcia-Reyero, 2011).

1.3 ADVANCEMENTS IN HIGH-THROUGHPUT ASSAYS
Although high-throughput screening (HTS) assays have long been used by the
pharmaceutical and pesticide industry to help prioritize lead candidates during early-stage
product development, the potential application of these assays for regulatory toxicology
is a relatively recent development. The purpose of these screens is to discover active
compounds that elicit an effect on a chemical pathway with the ultimate goal of helping
to identify the MOA. The term “high-throughput” is relative to the assay – it can range
from a semi-automated imaging process to a fully automated process using robotics.
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As of today, safety information for thousands of chemicals in commerce is
unknown. It is unrealistic and costly to test this large quantity of compounds using
traditional, whole-organism/in vivo methods, so cell lines/in vitro methods are often used
as the first tier of a tiered testing strategy. Although in vitro models do not provide the
physiological context and are difficult to extrapolate to whole organisms, these models
simplify exposure protocols, reduce the amount of test material needed, and allow for
identification of chemicals that interact with specific receptors, proteins, or other
molecules without the possibility of off-target effects. Nonetheless, the exploration and
use of in vivo models for HTS assays is currently on the rise as a second tier to examine
the interactions of a compound and a whole organism.

1.3.1 CURRENT USE OF HIGH-THROUGHPUT SCREENING (HTS)/ HIGH-CONTENT
SCREENING (HCS)
Due to advancements in technology and HTS/HCS methods, the use of these
methods has been on the rise. The National Institute of Health (NIH) is currently using
HTS assays as part of a relatively new toxicity testing strategy developed from the 2007
National Toxicology Program’s (NTP) “Vision and Roadmap for the 21st Century”
(Schmidt, 2009). As traditional toxicity tests are low-throughput, expensive, and use a
high number of animals, HTS/HCS methods are being utilized with the goal of moving
from an observational science at the level of disease-specific models to a predictive
science focused on target-specific and mechanism-based observations. In fact, the
toxicity testing paradigm is beginning to shift towards more high-throughput methods
that are often viewed as the best method of collecting data on thousands of chemicals that
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currently do not have any toxicity data (Schmidt, 2009). Currently, the NTP uses HTS
assays to: 1) prioritize substances for further, in-depth evaluation; 2) identify the MOA;
and 3) develop predictive models for in vivo biological response.
In 2008, to gain support for this shift in the toxicity testing paradigm, the NTP
entered into a five-year partnership, known as Tox21, with the EPA’s National Center for
Computational Toxicity (NCCT), and the National Human Genome Research Institute’s
NIH Chemical Genomics Center (NCGC), in which the NTP, NCCT, and NCGC have
expertise in experimental toxicology, computational toxicology, and high-throughput
technologies, respectively (Schmidt, 2009). The U.S. Food and Drug Administration
(FDA) was later added into the partnership and brought the expertise of human diseases
and animal models of human disease, as well as toxicity pathway analysis and
computational toxicology.
Within Phase I of the Tox21 initiative, each partner screened hundreds to
thousands of chemicals with HTS assays. The NCGC screened 2800 compounds in more
than 50 quantitative HTS (qHTS) assays using a 1536-well microtiter plate to test as
many as 15 concentrations per compound, allowing for concentration-response curves to
be generated. These concentration-response curves may provide better and more
information about low-dose human effects compared to traditional toxicity tests
(Schmidt, 2009). Using robots, the NCGC can process 100 plates per day, resulting in
over one million samples per week. Concurrently, the NCCT was screening 309
compounds in more than 500 biochemical- and cell-based assays in the ToxCast™
program that uses a multiple matrix approach, including in silico models, biochemical
assays, cell-based in vitro assays, and non-mammalian animal models (Dix et al., 2007).
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Parallel to other screens, the NTP tested the same 309 compounds on Caenorhabditis
elegans in the WormTox program. Within Phase II, the goal is to identify a full spectrum
of secondary and tertiary screening assays that will then be used to further define and
characterize activities identified in the initial screening process (Schmidt, 2009). The
Tox21 partners will test 10,000 compounds using the facilities at NCGC. Additionally,
the NCCT will test 700 compounds in ToxCast™. While in vitro and cell-based assays
may not provide the complex interactions that in vivo models offer, these assays do
provide a rapid first-tier screening system to identify chemicals of interest to test using
other alternative animal models like C. elegans or zebrafish.

1.3.2 ALTERNATIVE ANIMAL MODELS CURRENTLY USED IN HTS/HCS ASSAYS
Certain characteristics of traditional animal models (e.g., mice and rats) –
including high husbandry costs, large size, and difficulties with non-invasive imaging –
preclude the ability of these models to be used for HTC/HCS assays. Therefore, the use
of alternative animal models, including C. elegans, Drosophila melanogaster (fruit fly),
and Danio rerio (zebrafish) for HTS/HCS assays are on the rise. Numerous
characteristics make C. elegans an appropriate model for HTS/HCS assays and toxicity
tests including a rapid life cycle, high fecundity, transparency throughout all life stages,
and small size. The life cycle of C. elegans has been studied and reviewed extensively
(Corsi, 2006; Leung et al., 2008). Embryogenesis is a rapid, 13-hour cycle that begins
with in utero development until gastrula stage (30 cells) when the egg is laid and ex utero
development commences. After hatching, the larvae develop through four different stages
and finally molt, maturing into a hermaphroditic adult within three days. As
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hermaphroditic organisms, C. elegans are able to produce hundreds of genetically
identical offspring, which is advantageous for genetic screens (Hope, 1999). Due to the
small and transparent body, automated pipetting systems and high-throughput imaging
methods relying on absorbance, fluorescence, movement, and morphology have been
developed (Baek et al., 2002; Boyd et al., 2010; Giacomotto and Segalat, 2010; Gosai et
al., 2010). In fact, these nematodes have been used in many high-throughput assays to
estimate the toxicity of chemicals on several endpoints including growth and
reproduction (Boyd et al., 2010; Gosai et al., 2010). Additionally, the genome is well
annotated within WormBase (http://www.wormbase.org), an online and public reference
tool with information about the genetics, genomics, and biology of C. elegans (Harris et
al., 2004). Forward genetic techniques can also be utilized to understand the role of
different genes in mediating toxicity (Leung et al., 2008). Most importantly, many
biological pathways and stress responses seen in higher-level organisms are conserved in
C. elegans (Leung et al., 2008); however, some diseases cannot be modeled within C.
elegans because of a lack of homologous genes or organs (Giacomotto and Segalat,
2010), limiting the utility of these worms.
The fruit fly (D. melanogaster) was first used in the early 1900s as a genetic
model, but has evolved into an intensely studied model organism not only for genetics
but also in other areas including behavior, locomotion, and development (Branson et al.,
2009; Dankert et al., 2009; Jakubowski et al., 2012; Peng et al., 2007). Similar to C.
elegans, numerous characteristics make the fruit fly an appropriate model for HTS/HCS
assays and toxicity tests including rapid development, high fecundity, transparent
embryos, and small size. Fruit flies hatch from eggs with 12-15 hours after fertilization
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and continue to grow, molting at 24 and 48 hours before encapsulating themselves in a
paparium on day four. The larvae then undergo four days of metamorphosis, and emerge
as adult flies. D. melanogaster females can produce 100 eggs per day and have a short
generation time (~10 days), allowing for several generations to be studied within a few
weeks (Giacomotto and Segalat, 2010). Additionally, the genome was first published in
2000 (Adams et al., 2000) and is available via FlyBase (http://www.flybase.org), an
interactive online tool in which investigators can search for genetics, phenotypes,
sequences, stocks, and other information. Importantly, more than 60% of human genes
have functional orthologs within the fly (Reviewed in Giacomotto and Segalat, 2010),
which make this organism an important model in examining human diseases. The fly,
however, can not be grown in aqueous medium, limiting its uses in HTS/HCS studies and
drug screens. However, recent technological advancements have made HTS/HCS assays
using this fly possible. For example, D. melanogaster has been recently used in
HTS/HCS methods to identify the genes responsible for adverse crawling behavior
(Jakubowski et al., 2012) and drugs that modify food intake (Gasque et al., 2013). The
use of Drosophila for studies other than genetics is on the rise.

1.4 ZEBRAFISH AS AN ALTERNATIVE ANIMAL MODEL
While zebrafish, medaka, and rainbow trout have long been used as models for
developmental biology, genetics, and toxicology, zebrafish are the preferred fish model
for human disease (Lieschke and Currie, 2007), high-throughput drug discovery (Zon and
Peterson, 2005), and chemical toxicity screening (Hill et al., 2005). Zebrafish are often
considered as an alternative animal model that bridges the gap between invertebrates
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(worm and fly) to mammals (mouse and human) (Giacomotto and Segalat, 2010).
Numerous characteristics make the zebrafish a suitable model for toxicity screening
including rapid, ex utero development, high fecundity, transparency during
embryogenesis, and small size. Moreover, relative to larger animal models like rodents
and rainbow trout, zebrafish colony maintenance requires minimal start-up investments,
annual operational costs, personnel labor, and laboratory space.
Zebrafish embryogenesis is rapid (72 h from fertilization to hatch) and comprised
of seven developmental periods: zygote (0-0.75 hpf), cleavage (0.75-2.25 hpf), blastula
(2.25-5.25 hpf), gastrula (5.25-10 hpf), segmentation (10-24 hpf), pharyngula (24-48
hpf), and hatching (48-72 hpf) (Kimmel et al., 1995). Females can produce hundreds of
embryos each day, which is beneficial for high-throughput assays and provides
statistically significant sample sizes at a low cost. Transparent embryos also allow for the
use of transmitted light or fluorescence to assess gross morphology as well as multiple
organs such as the liver, heart, and nervous system. Additionally, since embryos develop
ex utero, developmental toxicity can be easily assessed since small hydrophobic
compounds (log Kow > 2) can be either directly absorbed by the embryo and larger
and/or hydrophilic compounds can be microinjected into the embryo during development.
The zebrafish embryo is approximately 1 mm in diameter and can survive in a 96-well
plate until 7 days post-fertilization (dpf) (McGrath and Li, 2008). Other important
characteristics of zebrafish are: (1) the genome is fully sequenced; (2) developing
embryos can be genetically altered with ease, which can help identify important genes
that regulate specific responses to compounds; and (3) a number of compounds elicit
similar effects to both humans and zebrafish because the substrate binding regions of
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zebrafish are almost 100% similar to that of humans (Langheinrich, 2003). Nevertheless,
a few disadvantages of using the zebrafish model in HTS/HCS assays include the limited
number of transgenic lines that produce high numbers of viable embryos and a lack of
appropriate tools to manipulate and analyze the copious amounts of data associated
HTS/HCS assays. Despite these limitations, the zebrafish model is a valuable and
increasingly used model for HTS/HCS assays.
The advantages associated with using zebrafish have led to the use of zebrafishbased developmental toxicity assays to evaluate the potential human health hazards of
960 unique chemicals within EPA’s ToxCast™ program. In this assay, wildtype
zebrafish are continuously exposed to individual chemicals in 96-well plates from ~8
hours post-fertilization (hpf) (late gastrula) to 5 days post-fertilization (dpf), and then
manually evaluated for mortality and gross malformations at 6 dpf (Padilla et al., 2012).
Following identification of positive chemicals from single-concentration limit tests (e.g.,
at 80 µM), multiple concentrations are tested to define the slope, median effective
concentration (EC50), and no-observable effect concentration (NOEC) of the
concentration-response curve. Although these types of assays are valuable for identifying
teratogenic and acutely lethal chemical concentrations, gross malformation-based
endpoints such as pericardial edema, body curvature, and craniofacial abnormalities often
lack chemical specificity, providing little to no information about the mechanism of
toxicity (molecular-level initiating event) and mode-of-action (key events leading to
disruption of organogenesis). Therefore, in order to enhance EPA’s existing zebrafish
embryo assays within ToxCast™, functional zebrafish-based assays are needed to better
evaluate targeted effects on organogenesis and classify chemicals by toxicologically

11

relevant AOPs. For example, the HCS assay discussed in Chapter 3 of this dissertation
enhances the ToxCast™ zebrafish embryo assay by providing a functional zebrafishbased assay that can evaluate targeted effects on angiogenesis and cardiovascular
development as well as classify chemicals by toxicologically relevant AOPs.

1.4.1 ZEBRAFISH AS A MODEL FOR NERVOUS SYSTEM DEVELOPMENT
The nervous system of zebrafish has been studied extensively over the last 25-30
years (Hjorth and Key, 2002; Kuwada et al., 1990; Myers et al., 1986). First, the
transparency of the zebrafish embryo allows for observation of the growing brain,
notochord, and spinal cord. Additionally, transgenic lines such as Tg(nkx2.2a:mEGFP)
make live imaging of the nervous system possible, and immunohistochemistry techniques
can be used to label many aspects of the nervous system within fixed individuals. The
nervous system is fully functional by 24 hpf, thus screening chemicals to investigate
effects on the nervous system can be completed quickly after initiation of exposure
following fertilization. Zebrafish have been also been utilized to assess locomotion
(Downes and Granato, 2004; Thomas et al., 2009) and, more recently, neurodegenerative
diseases (Fitzmaurice et al., 2013), all of which are directly related to successful
development of the nervous system. Finally, since the zebrafish genome is fully
sequenced, zebrafish can be used to examine the genes required for normal nervous
system development and which genes are affected when the organism is exposed to
neurotoxic compounds (Kluver et al., 2011).
Primary neurogenesis within the zebrafish, unlike other vertebrates, begins during
the segmentation period (10-24 hpf) when the first post-mitotic neurons become evident
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in the neural plate (Blader and Strahle, 2000; Hjorth and Key, 2002; Kimmel et al.,
1995). The primary motoneurons first appear on the ventral floor of the spinal cord and
migrate to their final destination within the spinal segments by 16 hpf (Myers et al.,
1986). By 18 hpf, the anterior neural tube and the posterior neural tube develop into ten
brain neuromeres and the spinal cord, respectively (Kimmel, 1993). Additionally, the
primary interneurons differentiate and establish axon tracts that extend within each brain
neuromere and spinal cord segment (Myers et al., 1986; Wilson et al., 1990). The primary
motoneurons then innervate the surrounding muscle fibers in a highly categorized, errorfree method (Hanneman et al., 1988; Myers et al., 1986), initiating the first movements of
the developing embryo – weak, spontaneous muscle contractions (Kimmel et al., 1995;
Myers et al., 1986). Subsequently, secondary motoneurons develop 5-6 hours after
development of the primary motoneurons (Myers et al., 1986). By 24 hpf, a fully
functional neural circuit is complete.

1.4.2 ZEBRAFISH AS A MODEL FOR CARDIOVASCULAR DEVELOPMENT
During the past decade, zebrafish have been examined as a potential model
organism for cardiovascular development. The zebrafish develops very rapidly with the
heart and vascular systems being fully functional by 48 hpf. Secondly, zebrafish
development is not dependent on a functional cardiovascular system (Bakkers, 2011;
Isogai et al., 2001). Unlike avian and mammalian models, zebrafish embryos can survive
on passive diffusion of oxygen, making it possible to examine severe cardiovascular
defects (Bakkers, 2011). Third, contrary to mammalian models, the transparency of the
zebrafish embryo and the availability of several transgenic lines allow for the
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cardiovascular system to be studied during early vascular development within live
animals (Bakkers, 2011). Lastly, since the zebrafish genome is fully sequenced, it is
possible to conduct forward genetic screens to identify genes responsible for normal
cardiovascular development as well as reverse genetic approaches to examine the role
and function of genes during development.
The heart is the first functional organ system of the vertebrate embryo (Flamme et
al., 1997); in fact, the heart begins to form within zebrafish during the gastrula period
(5.25-10 hpf) with the specification of the myocardial and endocardial progenitor cells
(Bakkers, 2011). Cardiac differentiation is then initiated by 16 hpf (Bakkers, 2011), and
the tube heart is lumenized and beating commences by approximately 22-25 hpf (Stainier
et al., 1993). By 36 hpf, the heart begins to loop towards the right lateral side (Stainier et
al., 1993) and is complete by 48 hpf (Glickman and Yelon, 2002) with the atrium and
ventricle located to the left and right of the midline, respectively, when orientated in
dorsal recumbency.
The heart is not the only organ growing during this window of development; the
vascular system is also beginning to evolve. Angioblasts first appear within the posterior
lateral plate mesoderm of the trunk at 12 hpf (Jin et al., 2005). By 20 hpf, arterial- and
venous-fated angioblasts begin to aggregate at the midline and form a vascular cord that
becomes lumenized (dorsal aorta (DA) primordium) by 22 hpf (Herbert et al., 2009).
Venous-fated angioblasts then sprout ventrally from the DA primordium and merge
around resident blood cells forming the lumenized caudal vein (CV) primordium by 26
hpf (Herbert et al., 2009). By 30 hpf – several hours after the heart begins to beat –
circulation commences through the fully formed DA and posterior caudal vein (PCV)
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(Herbert et al., 2009; Isogai et al., 2001). Unlike many vertebrates, the DA and PCV
within zebrafish are single, unpaired tubes when circulation commences in the trunk
(Isogai et al., 2001). By 36 hpf, the intersegmental vessels (ISV) begin to sprout and
elongate dorsally from the DA and PCV (Isogai et al., 2001). The ISVs then form a “T”
shape in the most dorsal region of the trunk and extend longitudinally to form the dorsal
longitudinal anastomotic vessels (DLAVs) (Childs et al., 2002; Isogai et al., 2001). By 48
hpf, the ISVs are lumenized and possess active circulation (Isogai et al., 2001), and the
majority of the cardiovascular system development is complete. Many studies suggest the
development of the vascular system within zebrafish is similar to other vertebrates
including humans and can be used as a model for human cardiovascular development and
health.

1.5 RESEARCH OBJECTIVES
As discussed above, scientifically sound models are needed to predict toxicity
without sole reliance on conventional whole-organism (vertebrate) bioassays. To help
address this challenge, AOPs have recently been proposed as conceptual tools to help link
direct, molecular-level initiating events to adverse outcomes at higher levels of biological
organization. Additionally, using AOPs as frameworks, HTS/HCS assays have been
recently proposed as key components of a tiered regulatory toxicity testing strategy that
enables screening and prioritization of chemicals for further testing using conventional
bioassays. Therefore, using zebrafish embryonic development as a model, the overall
research objectives of this dissertation were to 1) rely on paraoxon – the active metabolite
of the organophosphorus (OP) insecticide parathion – as a reference acetylcholinesterase

15

(AChE) inhibitor to examine whether the common molecular initiating event (AChE
inhibition) was associated with adverse neurological effects at higher levels of biological
organization and 2) develop and optimize a HCS assay to identify chemicals impacting
cardiovascular system function and potentially serve as a platform for guiding AOP
discovery and development.
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Figure 1.1: Generic diagram of an adverse outcome pathway.
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CHAPTER 2
ADVERSE OUTCOME PATHWAYS DURING ZEBRAFISH EMBRYOGENESIS: A CASE STUDY
WITH PARAOXON
2.1 INTRODUCTION
As fish embryos (pre-hatch stages) and eleuthereoembryos – the time-period
between immediately post-hatch and independent feeding – are non-protected life-stages,
these early life-stages are considered alternative testing models within the European
Union and United States (Belanger et al., 2010; Embry et al., 2010; Halder et al., 2010;
Scholz et al., 2008). In contrast to cell-based assays, fish embryos provide the
complexity and interaction of an intact organism, enabling the evaluation of adverse
chemical effects on multiple target organs and developmental stages during
embryogenesis. To begin testing the feasibility of developing alternative AOP-based
assays, the objective of this study was, using a well-studied reference chemical, to
develop an AOP that provided quantitative linkages across levels of biological
organization during zebrafish embryogenesis.
Organophosphorus (OP) insecticides are used for broad-spectrum insect control
on ornamentals, turf grass, and certain vegetable and field crops. These insecticides are
potent acetylcholinesterase (AChE) inhibitors that induce cholinergic toxicity via
acetylcholine (ACh) accumulation and activation of acetylcholine receptors (AChR)
localized to post-synaptic membranes (Pope, 1999). In fact, due to concerns about off-

18

target adverse effects on humans (in particular children), the use of OP insecticides for
indoor applications was eliminated in the United States in 2000-2001 (U.S. EPA, 2000;
U.S. EPA, 2001). For this study, we relied on paraoxon – the active metabolite of the OP
insecticide parathion – as a reference acetylcholinesterase (AChE) inhibitor to examine
whether the common molecular initiating event (AChE inhibition) was associated with
adverse neurological effects at higher levels of biological organization. Although two
previous studies have assessed the potential effects of paraoxon exposure on AChE
activity and development of 48-hpf zebrafish embryos (Kuster, 2005; Kuster and
Altenburger, 2006), these studies did not examine potential neurological effects within
later stages of embryogenesis (>48 hpf) nor assess recovery of AChE activity. As
zebrafish do not have butyrylcholinesterase (BChE) (Bertrand et al., 2001), we first
characterized the magnitude of ache expression at multiple stages throughout normal
zebrafish embryogenesis using real-time PCR. We then assessed the dynamics of
paraoxon-mediated AChE inhibition as a function of concentration, developmental stage,
and exposure duration (including the potential for recovery), as well as the effects of
paraoxon on the morphology of secondary motoneuron axons at 96 hpf. Finally, using a
locomotor behavior assay with 26-hpf embryos, we quantified the potential effects of
paraoxon on the frequency of spontaneous tail contractions.

2.2 MATERIALS AND METHODS
2.2.1 ANIMALS
Adult wild-type (5D) zebrafish were raised and maintained on a 14-h:10-h
light:dark cycle within an Aquatic Habitats Five-Shelf Stand-Alone recirculating system
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containing photoperiod enclosures and conditioned reverse osmosis (RO) water (~2728°C). Adult females and males were bred off- or on-system using breeding traps
suspended within 1- or 3-l tanks, respectively, to allow spawned eggs to settle to the tank
bottom. For all experiments described below, newly fertilized eggs were staged
according to previously described methods (Kimmel et al., 1995). All fish were handled
and treated in accordance with approved Institutional Animal Care and Use Committee
(IACUC) protocols at the University of South Carolina – Columbia.

2.2.2 TOTAL RNA ISOLATION AND REAL-TIME PCR
Three replicate pools of 12- to 98-hpf zebrafish (50 individuals per pool; nine
total developmental stages) were snap-frozen in liquid nitrogen and stored at -80°C.
Following homogenization of embryos using sterile blue polypropylene pestles, a SV
Total RNA Isolation System (Promega) was used to extract total RNA from pooled
embryo extracts per manufacturer’s instructions. Prior to sample elution, total RNA
samples were on-column-digested with DNase-I to remove any DNA contamination.
Total RNA concentrations and 260/280 ratios were determined using a NanoDrop ND2000 spectrophotometer and samples were stored at -80°C.
Per manufacturer’s instructions, first-strand cDNAs were generated from total
RNA samples using oligo(dT)15 primers and AMV Reverse Transcriptase (Promega); all
cDNA samples were stored at -20°C until use. ache and 18s rRNA cDNAs within each
developmental stage were amplified using the following primers: ache (185-bp
fragment), forward primer 5’-CACAGAGCCAATGAAGGTGCACAA-3’, reverse
primer 5’-TGCTGTAATGGTCGAACTGGCTCT-3’; and 18s rRNA (150-bp fragment),
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forward primer, 5’-TCGCTAGTTGGCATCGTTTATG-3’, reverse primer 5’CGGAGGTTCGAAGACGATCA-3’. As 18s rRNA is stably expressed throughout
zebrafish embryogenesis (McCurley and Callard, 2008), this gene was selected as an
internal control for each developmental stage. Per manufacturer’s instructions,
approximately 150 ng of ache and 18s rRNA cDNA were PCR-amplified using GoTaq®
qPCR Master Mix (Promega) and an Applied Biosystems 7900HT Fast Real-Time PCR
System. Real-time PCR reaction conditions were: 2 min at 95°C followed by 45 cycles
of 95°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec.
Relative quantitation of gene expression within each reaction was calculated using
the comparative cycle threshold (Ct) method. For each sample, the threshold cycle for
reference (18s rRNA) amplification (Ct, 18s rRNA) was subtracted from the threshold cycle
for target amplification (Ct, ache) to yield a ∆Ct. The Ct represents the cycle number at
which the fluorescence signal is significantly above the baseline. The mean and standard
deviation of ∆Ct were then calculated for each developmental stage, and the mean ∆Ct for
12 hpf was subtracted from the mean ∆Ct for each of the remaining developmental stages
to yield a mean ∆∆Ct. For each developmental stage, a mean fold change relative to 12
hpf was calculated using 2-∆∆Ct, and a standard deviation of the mean fold change was
calculated using 1/(2-∆Ct( )) in order to (1) assess the true variance (rather than 12-hpfσ

normalized variance) of the mean ∆Ct and (2) ensure that 2-∆Ct( ) values between zero and
σ

one were on an equivalent scale as mean fold changes greater than one.
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2.2.3 DEVELOPMENTAL PARAOXON EXPOSURES
Paraoxon-ethyl (100% purity) was purchased from AccuStandard, Inc. Stock
solutions of paraoxon were prepared by dissolving chemicals in HPLC-grade acetone; all
stock solutions were stored at -20°C. For each experiment, working solutions were
freshly prepared by spiking stock solutions into embryo media (EM) (5 mM NaCl, 0.17
mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4), resulting in 0.1% acetone within all vehicle
controls and treatment groups.
Glass beakers (50-mL capacity) were used for all exposures and, prior to each
experiment, thoroughly rinsed with solvent (acetone) and RO water. Immediately
following spawning, newly fertilized eggs were collected and placed in groups of
approximately 50 per petri dish within a light- and temperature-controlled incubator until
5 hpf. Viable 5D embryos (40 per treatment replicate) were exposed under static
conditions to vehicle (0.1% acetone) or water-borne paraoxon (31.2 to 500 nM) within
triplicate glass beakers and incubated at 28°C under a 14-h:10-h light:dark cycle. At 96
hpf, all surviving larvae were euthanized with an overdose of tricaine methanesulfonate
(MS-222, 200-300 mg/L) and evaluated under transmitted light for the following
developmental abnormalities: decreased body length, craniofacial malformations, trunk
curvature, tail malformations, pericardial edema, and yolk sac edema. For AChE assays,
three replicate pools of 96-hpf larvae (eight individuals per pool; one pool per replicate
beaker) were transferred to 1.5-ml microcentrifuge tubes and, following aspiration of
EM, samples were stored at -20°C until assay initiation. For in situ imaging assessments
of secondary motoneurons, 96-hpf larvae were fixed overnight in 4%
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paraformaldehyde/phosphate-buffered saline (PBS) at 4°C and then stored in 1X PBS at
4°C until imaging.
To quantify AChE activity over time, embryos were exposed as above to vehicle
(0.1% acetone) or 500 nM paraoxon from 5 to 96 hpf, euthanized at 24, 48, 72, and 96
hpf, and stored as described above. To identify potential recovery of AChE activity after
exposure to paraoxon, embryos were exposed as above to vehicle (0.1% acetone) or 500
nM paraoxon during each of the following developmental windows: gastrula and
segmentation (5-24 hpf); pharyngula (24-48 hpf); hatching (48-72 hpf); or early larval
(72-96 hpf). If exposed prior to 72 hpf, embryos were rinsed several times and
transferred to clean EM until 96 hpf. At 96 hpf, all larvae were euthanized and stored as
described above.

2.2.4 ACETYLCHOLINESTERASE ASSAYS USING WHOLE EMBRYO OR LARVAL
HOMOGENATES
A microassay method for determination of AChE activity within whole zebrafish
embryo or larval homogenates was adapted from a previously published endpoint-based
protocol for mammalian and avian tissue homogenates (Correll and Ehrich, 1991). For
each treatment group, three replicate pools of embryos or larvae (eight individuals per
pool; one pool per replicate beaker) were homogenized in 200 µl of cold 0.1 M phosphate
buffer using a PowerGen Model 35 Handheld Homogenizer (Fisher Scientific) and
immediately placed on ice. Prior to homogenizing each sample, the homogenizer was
rinsed twice in RO water, and water was wicked away from the homogenizer using a
ChemWipe. For each reagent blank and sample, 150 µL of 0.1 M phosphate buffer and
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50 µL of 0.01 M dithiobisnitrobenzoic acid (DTNB) solution was added to a clean 1.5-ml
microcentrifuge tube. For each reagent blank (3 total), 50 µL of phosphate buffer was
added to each tube containing phosphate buffer and DTNB solution. For each sample, 50
µL of embryo or larval homogenate was added to each tube containing phosphate buffer
and DTNB solution. After mixing blanks or samples by pipetting several times, 50 µL of
0.075 M acetylthiocholine iodide was added to each blank or sample tube and mixed
again by pipetting several times. The final concentrations of DTNB and
acetylthiocholine iodide were 0.003 M and 0.019 M, respectively. All blanks and
samples were immediately transferred to a clear 96-well microplate and initial
absorbance at 490 nm was measured using a Perkin Elmer Victor X3. Although
absorbance for this assay has historically been measured between 405 to 412 nm
(Adewusi and Steenkamp, 2011; Ellman et al., 1961), we found that readings at 490 nm
provided better separation of blank and control sample absorbance readings. The plate
was incubated at 37oC for 30 min, and absorbance was measured again at 490 nm after
the wells were mixed by pipetting several times. An incubation time of 30 min was
selected for the AChE microassay, as this duration yielded (1) maximum absorbance
within control embryo or larval homogenates; (2) non-detectable absorbance within
reagent blank samples; and (3) as a result, maximum assay sensitivity and potential for
detection of paraoxon-mediated AChE inhibition.
To quantify total protein within each homogenate, 300 µL of Coomassie Plus
Bradford Assay Reagent (ThermoScientific) was added to the appropriate number of
wells within a clear 96-well microplate, and 10 µL of 0.1 M phosphate buffer (blank),
homogenate, or six different bovine serum albumin (BSA) standards (100 to 1500
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µg/mL) prepared in 0.1 M phosphate buffer was then added to wells containing assay
reagent. After mixing contents of the wells by pipetting up and down several times, the
plate was incubated for 10 min and absorbance of BSA standards and samples was
measured using a Perkin Elmer Victor X3 Microplate Reader.
For the first and second readings, average blank absorbance was subtracted from
the sample absorbance to account for non-enzymatic hydrolysis of substrate. The rate of
change was calculated for each sample using the following equation (Correll and Ehrich,
1991; Ellman et al., 1961): Rate (moles/L per min) = ((Abst1 – Abst0 / 30 min) /
1.36X104). The estimated rate of change was then normalized to total protein using the
following equation: Rate (moles/L per min per mg) = (Change in Abs. / 1.36X104) / mg
protein. Percent decrease (or inhibition) of AChE activity was calculated relative to
vehicle controls.

2.2.5 IN SITU IMAGING ASSESSMENTS OF SECONDARY MOTONEURONS WITHIN 96-HPF
LARVAE
To remove pigmentation and enhance fluorescence imaging in vivo, fixed 96-hpf
larvae (four individuals per treatment) were incubated for 30 min at room temperature in
fresh 3% H2O2/0.5% KOH and then washed in PBS for 5 min to stop the bleaching
reaction. To allow adequate antibody penetration within all tissues, bleached
(transparent) larvae were permeabilized by incubating in cold acetone at -20°C for 30
min and then rinsing four times in PBS/0.1% Tween-20 (PBST) for 5 min per wash.
Permeabilized larvae were incubated in fresh blocking buffer (PBST/2% sheep serum/2
mg/ml bovine serum albumin) for 4 h at room temperature with gentle agitation and then
25

incubated overnight at 4°C with gentle agitation in blocking buffer containing a 1:20
dilution of zn-8 IgG1 supernatant. zn-8 IgG1 is a zebrafish-specific antibody that
recognizes neuronal cell surface markers within the central and peripheral nervous
system of developing zebrafish (Trevarrow et al., 1990). Following incubation in
primary antibodies, larvae were washed five times with gentle agitation in PBST at room
temperature for 15 min each. Larvae were then incubated overnight at 4°C with gentle
agitation in blocking buffer containing a 1:500 dilution of Alexa Fluor 488 (AF488)conjugated goat anti-mouse IgG1 (Invitrogen) to visualize zn-8 localization in situ.
Finally, secondary antibody-labeled larvae were washed five times with gentle agitation
in PBST at room temperature for 15 min each, and then stored in PBS at 4°C until
imaging.
The zn-8-labeled larvae were mounted within 80% glycerol on a standard
microscope slide and imaged using an Olympus FluoView FVX IX70 laser-scanning
confocal microscope. For imaging the trunk, fish were oriented in right lateral
recumbency and focused under transmitted light using a 10X objective. An XYZ optical
sectioning mode was used to image AF488 fluorescence within segments 7, 8, and 9 of
each larval trunk using a total of 12 sagittal confocal sections at a 5-µm Z-step interval.
Based on our preliminary data, 12 confocal sections and a 5-µm Z-step interval provided
complete coverage of secondary motoneurons within 96-hpf larvae. Following
acquisition at different depths, composite Z-stack images for each individual were
generated to provide a final merged image for quantitative analysis within Olympus’
FluoView software. The following endpoints were assessed to determine whether
paraoxon exposure impacted secondary motoneuron axon growth and pathfinding: 1)

26

presence or absence of ventral, medial, and dorsal motoneuron axons; 2) length of
ventral, medial, and dorsal motoneuron axons; and 3) presence of motoneuron axonal
pathfinding errors.

2.2.6 QUANTIFICATION OF SPONTANEOUS TAIL CONTRACTIONS WITHIN 26-HPF EMBRYOS
When reared at 28.5°C, spontaneous tail contractions within dechorionated
zebrafish embryos first appear at 17 hpf, with a peak frequency at 19 hpf and gradual
decrease by 27 hpf (Saint-Amant and Drapeau, 1998). When chorionated 5D embryos
are reared at 28°C (based on our own preliminary data), spontaneous tail contractions are
delayed, resulting in a peak frequency at 26 hpf. Therefore, we evaluated locomotor
behavior at 26 hpf within chorionated embryos to maximize assay sensitivity and
eliminate potential confounding effects due to pronase treatment and embryo handling.
Viable 5D embryos (40 per treatment replicate) were exposed to vehicle (0.1% acetone)
or water-borne paraoxon (31.2 to 500 nM) within triplicate glass beakers and incubated at
28°C under a 14-h:10-h light:dark cycle until 25 hpf. All embryos remained within the
glass beakers containing the treatment solution and were allowed to acclimate to room
temperature for one hour prior to imaging. At 26 hpf, all embryos within each treatment
beaker were continuously videoed once for 25 s under transmitted light using an
Olympus MVX10 MacroView stereomicroscope equipped with an Olympus DP72
Digital Color Camera and Olympus DP2-BSW Imaging Software. The number of tail
flips per 25 s was then counted for each surviving and non-malformed embryo within
each treatment. Any surviving embryos containing tail malformations were not counted
nor included within the final dataset since these embryos were unable to produce similar
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locomotion compared to the vehicle control embryos.

2.2.7 STATISTICAL ANALYSES
All statistical procedures were performed using SPSS Statistics 19.0. A general
linear model (GLM) analysis of variance (ANOVA) (α = 0.05) was used for all real-time
PCR, AChE activity, axon length, and behavioral assay data, as these data did not meet
the equal variance assumption for non-GLM-based ANOVAs. Pair-wise Tukey-based
multiple comparisons of least square means were performed to identify significant stageor treatment-related effects.

2.3 RESULTS
2.3.1 ACHE TRANSCRIPTS RAPIDLY INCREASE FOLLOWING SEGMENTATION
To assess ache expression during zebrafish embryogenesis, we extracted total
RNA from nine different developmental stages (12 to 98 hpf) and, following cDNA
synthesis, PCR-amplified a 185-bp ache fragment from each stage using real-time PCR.
Relative to 12 hpf, there was a rapid stage-dependent increase in ache transcript levels
from early-pharyngula (26 hpf) through the end of the early larval period (98 hpf) (Figure
2.1). Although levels were not significantly higher within pharyngula-stage embryos,
ache expression was, on average, approximately 25- and 60-fold higher during hatching
and early larval periods, respectively, relative to 12 hpf (Figure 2.1). Even though ache
expression was detected during segmentation, these data suggest that ache transcription is
not strongly activated until completion of segmentation and initiation of secondary
neurogenesis.
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2.3.2 PARAOXON-INDUCED ACHE INHIBITION IS DEPENDENT ON DEVELOPMENTAL STAGE
AND CONCENTRATION

To address the potential interaction of developmental stage and paraoxon
concentration on AChE activity, we exposed developing zebrafish embryos to paraoxon
from 5 to 96 hpf and used a modified Ellman assay to determine the rate of AChE
activity within homogenates from whole embryos or larvae. Based on these experiments,
we found a stage-dependent increase in AChE activity in vehicle controls but not 500-nM
paraoxon treatments (Figure 2.2A). In addition, there were significant within-stage
differences in AChE activity between vehicle control and 500 nM paraoxon treatments at
72 and 96 hpf but not 24 or 48 hpf (Figure 2.2A). When embryos were exposed to
increasing concentrations of paraoxon (31.2 to 500 nM), AChE activity within 96-hpf
larvae decreased in a concentration-dependent manner, with significant AChE inhibition
first detected at 62.5 nM paraoxon (Figure 2.2B). At the highest paraoxon concentration
tested (500 nM), AChE activity was decreased by approximately 85% compared to
vehicle controls (Figure 2.2B), demonstrating that exposure of developing zebrafish
embryos to 500 nM paraoxon nearly eliminated the ability of AChE to hydrolyze
acetylcholine (ACh) within 96-hpf larvae.

2.3.3 PARAOXON-INDUCED ACHE ACTIVITY RECOVERS FOLLOWING TRANSFER TO CLEAN
WATER
To determine whether the effects of paraoxon on AChE activity were reversible,
developing zebrafish embryos were exposed to paraoxon during discrete developmental
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windows and allowed to recover in clean water until 96 hpf. Similar to results presented
in Figure 2.2A, AChE activity increased as a function of developmental stage within
vehicle control embryos (Figure 2.3). However, AChE activity within embryos exposed
to 500 nM paraoxon from 24 to 48 hpf was inhibited by 76% and 29% at 48 and 72 hpf,
respectively, but returned to levels similar to vehicle controls by 96 hpf (Figure 2.3).
Likewise, AChE activity within embryos exposed to 500 nM paraoxon from 48 to 72 hpf
was inhibited by 89% and 35% at 72 and 96 hpf, respectively (Figure 2.3). However, the
recovery duration (24 h) within this treatment group was insufficient for AChE activity to
fully recover when embryos were transferred into clean water. Overall, we found that
paraoxon-induced effects on AChE activity were reversible, with full recovery in AChE
activity by 48 h after transferring to clean water (Figure 2.3).

2.3.4 PARAOXON DOES NOT AFFECT SECONDARY MOTONEURON AXON MORPHOLOGY
As exposure to 500 nM paraoxon resulted in trunk malformations and decreased
body length, we focused our imaging analyses on 96-hpf larvae exposed to sub-lethal,
non-teratogenic paraoxon concentrations (≤250 nM) in order to minimize potential
confounding effects of gross abnormalities on axon morphology. Therefore, we first
exposed developing zebrafish to increasing, non-teratogenic concentrations of paraoxon
(31.2 to 250 nM) from 5 to 96 hpf, and then used whole-mount immunohistochemistry
and confocal microscopy to label and image secondary motoneurons in situ. Normal
development and survival was >90% within vehicle controls and all paraoxon
concentrations tested. Relative to vehicle controls, we found no significant differences in
96-hpf larval body height or length following exposure to all non-teratogenic paraoxon
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concentrations tested (Figure 2.4A and 2.4B). Moreover, we found no significant effects
on secondary motoneuron axon abundance and pathfinding (data not shown), nor dorsal,
medial, and ventral axon lengths within paraoxon-exposed larvae compared to vehicle
controls (Figure 2.4C and 2.4D).

2.3.5 PARAOXON INCREASES THE FREQUENCY OF SPONTANEOUS TAIL CONTRACTIONS
WITHIN 26-HPF EMBRYOS
To determine whether paraoxon affected spontaneous locomotor behavior,
developing embryos were exposed to paraoxon (31.2 to 500 nM) from 5 to 26 hpf and the
frequency of spontaneous tail contractions was assessed at 26 hpf. Normal development
and survival was >95% within vehicle controls and all paraoxon concentrations tested. As
no significant differences among within-treatment replicates were detected (p>0.05), all
individuals within each treatment were combined for statistic analysis. Compared to
vehicle controls, we observed a significant increase in the frequency of spontaneous tail
contractions following exposure to paraoxon concentrations as low as 31.2 nM (the
lowest concentration tested) (Figure 2.5).

2.4 DISCUSSION
Using paraoxon as a reference AChE inhibitor, the objective of this study was to
develop an AOP that provided quantitative linkages across levels of biological
organization during zebrafish embryogenesis. Within normal embryos, we first
demonstrated that ache transcripts and AChE activity rapidly increased in a stagedependent manner following segmentation. We then showed that static exposure of
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embryos to paraoxon from 5 to 96 hpf resulted in significant stage- and concentrationdependent AChE inhibition, albeit AChE activity returned to vehicle control levels within
48 h following transfer to clean water. Even in the presence of significantly decreased
AChE activity, exposure to non-teratogenic paraoxon concentrations (≤250 nM) did not
lead to adverse effects on secondary motoneuron axon morphology nor obvious effects
on larval swimming behavior at 96 hpf based on preliminary observations under
transmitted light (data not shown). Therefore, we investigated the potential effects of
paraoxon exposure on locomotor behavior at 26 hpf (rather than larval swimming
behavior), and found that exposure to paraoxon concentrations as low as 31.2 nM (the
lowest concentration tested) significantly increased the frequency of spontaneous tail
contractions compared to vehicle controls. Importantly, this paraoxon-induced effect on
spontaneous behavior occurred at an early embryonic stage when minimal AChE
expression and activity was present relative to hatching- and early larval-stage embryos.
Based on real-time PCR, we found that ache expression within normal embryos
was detected during somitogenesis and rapidly increased following segmentation through
completion of the early larval period. Although we did not localize ache expression
within developing embryos, our real-time PCR data suggest that the rapid increase in
ache expression coincided with the onset of secondary neurogenesis. Based on wholemount in situ hybridization, previous studies have demonstrated that ache transcripts first
appear within primary motoneurons of the rostral spinal cord between 12 to 14 hpf and,
by the end of segmentation, are localized within primary neurons – including sensory
neurons, reticulospinal interneurons, and primary motoneurons – of the entire spinal cord
and hindbrain (Bertrand et al., 2001; Hanneman and Westerfield, 1989). Although ache
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expression is detected within developing axons, the majority of ache transcripts are
localized to cell bodies of primary and secondary neurons during early zebrafish
embryogenesis (Bertrand et al., 2001). While ache mRNA localization has, to our
knowledge, not been assessed beyond 27 hpf, we suspect that high levels of ache
expression during hatching- and early larval-stage zebrafish embryos are associated with
a dense population of secondary neuron cell bodies within the trunk and cranial regions.
Within control embryos, we observed a stage-dependent increase in AChE
activity that coincided with the timing of increased ache expression. However, exposure
to 500 nM paraxon from 5 to 96 hpf resulted in near elimination of AChE activity (>80%
inhibition) at 72 and 96 hpf, a finding that is consistent with previous studies reporting a
40% and 98% decrease in AChE activity following exposure to approximately 400 and
800 nM paraoxon, respectively, from 0.5 to 48 hpf (Kuster, 2005; Kuster and
Altenburger, 2006). Likewise, exposure of zebrafish embryos to 300 nM chlorpyrifos
from 6 to 96 hpf resulted in an 81% decrease in AChE activity by 96 hpf (Yen et al.,
2011), and exposure to 300 nM chlorpyrifos-oxon (the neurotoxic metabolite of
chlorpyrifos) from 24 to 72 hpf resulted in an 88% decrease in AChE activity by 72 hpf
(Yang et al., 2011). Our results also demonstrated that, similar to previous studies using
other AChE inhibitors within different experimental systems (Arduini et al., 2007; Jiang
et al., 2012), paraoxon-induced effects on AChE inhibition were fully reversible within
48 h of being transferred to clean water. Moreover, the timing of paraoxon exposure
during zebrafish embryogenesis did not impact the magnitude of recovery, demonstrating
that all developmental windows tested were equally susceptible to paraoxon-mediated
AChE inhibition. Although we did not quantify internal embryonic paraoxon doses, our
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data suggest that reversible effects on AChE inhibition following transfer to clean water
may be a result of (1) paraoxon metabolism and elimination (and ultimately dissociation
of paraoxon from AChE), (2) rapid degradation of inhibited AChE, and/or (3) increased
production of non-inhibited AChE – and, as a result, dilution of inhibited AChE – during
later stages of embryogenesis. Regardless of the mechanism of recovery, our results
suggest that transient, short-term exposures to paraoxon during zebrafish embryogenesis
do not lead to persistent effects on AChE activity.
Although we observed a significant concentration-dependent decrease in AChE
activity within 96-hpf larvae, exposure from 5 to 96 hpf to all paraoxon concentrations
tested (31.2 to 250 nM) resulted in no significant impacts on embryonic development and
secondary motoneuron axon morphology, findings that are consistent with previous
studies demonstrating that <80% AChE inhibition does not result in abnormal
development of 48-hpf zebrafish embryos (Kuster, 2005; Kuster and Altenburger, 2006).
However, contrary to our results with paraoxon, non-teratogenic concentrations of
chlorpyrifos-oxon (100 nM) significantly inhibited axonal growth of primary and
secondary motoneurons, as well as Rohon-Beard and dorsal root ganglia sensory neurons,
within developing zebrafish embryos (Jacobson et al., 2010; Yang et al., 2011), an effect
that was hypothesized to be mediated via disruption of the morphogenic activity of AChE
(Yang et al., 2011). As such, although both are potent AChE inhibitors at similar
nominal exposure concentrations, paraoxon and chlorpyrifos-oxon appear to exhibit
distinct downstream effects on secondary neurogenesis, a discrepancy that is consistent
with the long-standing conclusion that, while sharing a common target (AChE), all OP
insecticides do not share identical mechanisms of toxicity (Pope, 1999). While our
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investigations were focused on secondary motoneurons, our findings are also consistent
with previous studies that have reported no effects on primary neurogenesis following
deletion of the catalytic and/or neuritogenic carboxy-terminal domains of AChE within
zebrafish (Behra et al., 2002; Downes and Granato, 2004). Therefore, compared to data
generated using ache mutant lines, our data with paraoxon support the conclusion that
catalytic AChE function is dispensable for motoneuron development with zebrafish
embryos.
As exposure to non-teratogenic paraoxon concentrations did not impact larval
swimming behavior at 96 hpf based on preliminary observations under transmitted light,
we evaluated the potential effects of paraoxon exposure on spontaneous tail contractions
at 26 hpf – an early locomotor behavior that (1) results from innervation of primary (not
secondary) motoneuron axons to target axial muscles (Myers et al., 1986; Westerfield et
al., 1986) and (2) occurs in the absence of cues such as touch (Brustein et al., 2003;
Kimmel et al., 1972; Saint-Amant and Drapeau, 1998). Even in the presence of minimal
AChE activity, the frequency of spontaneous tail contractions was significantly higher
within 26-hpf embryos exposed to all paraoxon concentrations tested (31.2 to 500 nM).
Therefore, this adverse outcome (spontaneous behavior) was sensitive to paraoxon
exposure in the absence of significant AChE expression and activity and, as such, may be
mediated via paraoxon-induced activation of ACh receptors (AChRs) and/or disruption of
non-cholinergic signaling (Figure 2.6).
Although nicotinic and muscarinic AChRs are present within primary
motorneuron axons during early zebrafish embryogenesis (Behra et al., 2002), high
(millimolar) ACh concentrations are required to significantly increase locomotor
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behavior within dechorionated 28-hpf embryos (Thomas et al., 2009), suggesting that
endogenous ACh concentrations are likely too low for sustained AChR activation and
production of motor output. However, exposure to micromolar nicotine concentrations
increases the frequency of spontaneous tail contractions at 28 hpf (Thomas et al., 2009),
demonstrating that, at minimum, nicotinic AChRs are functional at this stage. Similar to
nicotine, paraoxon-induced effects on spontaneous tail contractions may, in part, be
mediated through direct activation of AChRs since (1) our data show that AChE activity
is virtually absent at this stage and (2) previous studies have demonstrated that paraoxon
competitively inhibits agonist binding to electric ray (Torpedo sp.) nicotinic AChR, albeit
the effective concentration was two orders of magnitude higher than the concentration
required to inhibit 50% of AChE activity (Katz et al., 1997).
On the other hand, Drapeau and colleagues have suggested that spontaneous
locomotion within embryonic zebrafish is regulated by electrical coupling-type
mechanisms rather than classical mechanisms of chemical neurotransmission since
spontaneous contractions were inhibited by gap junction blockers but were not affected
by glycine and glutamate receptor antagonists nor botulinum toxin (a broad-spectrum
inhibitor of synaptic transmission) (Brustein et al., 2003; Saint-Amant and Drapeau,
2000, 2001). Prior to formation and maturation of chemical synapses, gap junctions play
a critical role in linking spinal cord neurons and propagating spontaneous, electrical
current-driven depolarization within the motor network (Saint-Amant and Drapeau,
2001). Therefore, in addition to direct AChR activation, paraoxon-induced effects on
spontaneous behavior within zebrafish embryos may be due to abnormal development
and function of gap junction-mediated networks, a mechanism of toxicity that is

36

independent of classical cholinergic signaling.
In summary, our data suggest that (1) normal AChE activity is not required for
secondary motoneuron development and (2) AChE inhibition may not be associated with
an increased frequency of spontaneous tail contractions at 26 hpf following paraoxon
exposure. Although paraoxon was a potent AChE inhibitor within zebrafish embryos, this
initiating event was not linked to adverse outcomes on secondary motoneuron
development at 96 hpf and was fully reversible within 48 h following transfer of embryos
to clean water. Moreover, the most sensitive paraoxon-induced adverse outcome in this
study – an increased frequency of spontaneous tail contractions at 26 hpf – occurred in
the absence of significant AChE activity. While it’s unclear whether paraoxon-induced
effects on spontaneous behavior are mediated through direct AChR activation and/or
effects on non-cholinergic signaling, this adverse outcome at 26 hpf did not lead to
adverse impacts on secondary motoneuron development and larval swimming behavior
later in development (96 hpf), suggesting that primary neurogenesis is more sensitive to
paraoxon exposure than secondary neurogenesis. In addition, increased tail flip behavior
may be indicative of hyperactivity, a common neurological effect associated with OP
insecticides, and may result in an increase in energy expenditure. As such, while we
agree that AOPs are useful frameworks for facilitating development of chemical
screening and prioritization strategies, this case study using a potent reference chemical
highlights the potential challenges in developing AOPs that provide quantitative linkages
from molecular initiating events to endpoints relevant for human or ecological risk
assessments.
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Figure 1.1: ache transcripts rapidly increase following segmentation.

Figure 2.1: ache transcripts rapidly increase following segmentation. Relative to 12 hpf,
a significant increase in ache expression was detected beginning at 50 hpf. Fold change
data are mean ± standard deviation relative to 12 hpf. An asterisk denotes a significant
difference from 12 hpf (p<0.05). N = three replicate pools of 50 embryos per pool.
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Figure 2: Paraoxon-induced AChE inhibition is dependent on developmental stage and concentration

Figure 2.2: Paraoxon-induced AChE inhibition is dependent on developmental stage (A)
and concentration (B). In Panel A, an asterisk denotes a significant difference relative to
24 hpf within the same treatment (p<0.05), and a number sign denotes a significant
difference from vehicle controls within the same stage (p<0.05). In Panel B, an asterisk
denotes a significant difference from vehicle controls (p<0.05). N = three replicate pools
of eight 96-hpf larvae per pool.
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Figure 3: Paraoxon-induced effects on AChE activity are reversible following transfer to clean water.

Figure 2.3: Paraoxon-induced effects on AChE activity are reversible following transfer
to clean water. An asterisk denotes a significant difference relative to 24 hpf within the
same treatment (p<0.05), whereas a number sign denotes a significant difference from
vehicle controls within the same stage (p<0.05). N = three replicate pools of eight 96-hpf
larvae per pool.
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Figure 4: Paraoxon does not affect secondary motoneuron axon morphology

Figure 2.4: Paraoxon does not affect secondary motoneuron axon morphology. Panels A
and B show the gross morphology of 96-hpf larvae following exposure to vehicle (0.1%
acetone) or the highest non-teratogenic paraoxon concentration tested (250 nM),
respectively. Panel C shows a representative confocal Z-stack image of secondary
motoneurons within the trunk of a vehicle-treated 96-hpf fish (dorsal, medial, and ventral
axons are labeled). Panel D shows axon length data for secondary motoneurons within
96-hpf larvae following exposure to vehicle (0.1% acetone) or paraoxon (31.2 to 250
nM). N = three segments per individual and four larvae per treatment. No significant
differences were detected across all treatments.
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Figure 5: Paroxon increases the frequency of spontaneous tail contractions within 26-hpf embryos

Figure 2.5: Paraoxon increases the frequency of spontaneous tail contractions within 26hpf embryos. Box plots show the 25th, 50th, and 75th percentile for each treatment tested,
and error bars below and above the box represent the 10th and 90th percentile,
respectively. Filled circles represent data points less than or greater than the 10th or 90th
percentile, respectively. Treatments that do not share the same letter are significantly
different (p<0.05) from each other. All individuals within each treatment were combined
for statistic analysis since no significant differences among within-treatment replicates
were detected (p>0.05). Therefore, sample sizes reflect the total number of embryos
evaluated across all treatment replicates.

42

Figure 6: Proposed AOP for paraoxon exposure during early zebrafish embryogenesis (5 to 26 hpf)

Figure 2.6: Proposed AOP for paraoxon exposure during early zebrafish embryogenesis
(5 to 26 hpf). Dotted line denotes a minor contribution to the AOP since spontaneous
behavior was sensitive to paraoxon exposure in the absence of significant AChE activity.
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CHAPTER 3
HIGH-CONTENT SCREENING ASSAY FOR IDENTIFICATION OF CHEMICALS IMPACTING
CARDIOVASCULAR FUNCTION IN ZEBRAFISH EMBRYOS
3.1 INTRODUCTION
High-content screening (HCS) assays using zebrafish have been developed to
evaluate locomotion (Ingebretson and Masino, 2013; Mirat et al., 2013); nanoparticle and
chemical exposures (Lin et al., 2013; Padilla et al., 2012); bacterial infections (Veneman
et al., 2013); energy expenditure (Renquist et al., 2013); and drug-induced heart
malformations and impacts on cardiac function (Burns et al., 2005; Spomer et al., 2012;
Tran et al., 2007; Wen et al., 2012). Despite significant advancements, targeted HCS
assays using zebrafish are still needed to better evaluate chemical effects on
organogenesis and begin classifying chemicals by toxicologically relevant MOAs.
Therefore, the objective of this study was to develop a 384-well-based HCS assay with
sufficient power, replication, and exposure concentrations to screen and identify
chemicals that affect cardiovascular function at sub-lethal, non-teratogenic
concentrations.

3.2 MATERIALS AND METHODS
3.2.1 ANIMALS
For all assays described below, we relied on a robust line of transgenic zebrafish
(fli1:egfp) that stably express enhanced green fluorescent protein (eGFP) within vascular
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endothelial cells (Lawson and Weinstein, 2002). Adult fli1:egfp zebrafish were
maintained on a 14-h:10-h light:dark cycle within a Mini Mass Embryo Production
System (mini-MEPS) (Aquatic Habitats, Inc., Apopka, FL) containing a photoperiod light
cycle dome and recirculating conditioned reverse osmosis (RO) water (~27-28°C). Adult
females and males were bred directly within the mini-MEPS, or bred off-system within a
light- and temperature-controlled incubator using breeding traps suspended within 1-L
tanks. For all experiments described below, newly fertilized eggs were staged according
to previously described methods (Kimmel et al., 1995). All fish were handled and treated
in accordance with approved Institutional Animal Care and Use Committee (IACUC)
protocols at the University of South Carolina – Columbia, South Carolina.

3.2.2 CHEMICALS
Chemicals were purchased from ChemService, Inc. (West Chester, PA), Tocris
Bioscience (Bristol, UK), and Cambridge Isotope Laboratories, Inc. (Andover, MA);
chemical names, chemical formulas, CAS registry numbers, and purities are provided
within Table A.1. Stock solutions of each chemical were prepared by dissolving
chemicals in HPLC-grade dimethyl sulfoxide (DMSO), and then performing two-fold
serial dilutions into DMSO to create stock solutions for each working solution. All stock
solutions were stored at room temperature within 2-mL amber glass vials containing
polytetrafluoroethylene (PTFE)-lined caps. For each assay, working solutions of tricaine
methanesulfonate (MS-222) (Western Chemical, Inc., Ferndale, WA) were freshly
prepared by dissolving MS-222 into embryo media (EM) (5 mM NaCl, 0.17 mM KCl,
0.33 mM CaCl2, 0.33 mM MgSO4), and working solutions of all treatments were freshly
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prepared by spiking stock solutions into EM, resulting in 0.1% DMSO within all vehicle
control and treatment groups.

3.2.3 HIGH-CONTENT SCREENING (HCS) ASSAY
EXPOSURE SETUP. Black 384-well microplates containing 0.17-mm glass-bottom
wells (Matrical Bioscience, Spokane, WA) were used for all HCS assays. Immediately
following spawning, newly fertilized eggs were collected and placed in groups of
approximately 50 per glass petri dish within a light- and temperature-controlled incubator
until 5 hours post-fertilization (hpf). For each HCS assay, 384 viable fli1:egfp embryos
were arrayed at 5 hpf into a 384-well plate (one embryo per well) containing 50 µL per
well of vehicle (0.1% DMSO) or treatment solution, and then incubated at 28°C under a
14-h:10-h light:dark cycle and static conditions until 72 hpf.
IMAGE ACQUISITION. At 72 hpf, the plate was removed from the incubator, and
zebrafish embryos were anesthetized with 100 mg/L MS-222 by adding 25 µL of 300
mg/L MS-222 to 50 µL of vehicle or treatment solution. The plate was then centrifuged
at 200 rpm for 2 minutes to help orient hatched embryos into right or left lateral
recumbency. Using automated image acquisition protocols and parameters (Yozzo et al.,
2013b) optimized for our ImageXpress® Micro (IXM) Widefield High-Content Screening
System (Molecular Devices, Sunnyvale, CA), each embryo was imaged to analyze the
following endpoints: heart rate; circulation; pericardial area; body length; and
intersegmental vessel area (Figure 3.1). During the entire image acquisition period,
internal temperature within the IXM system was maintained between 25-27°C by
removing panels on both sides of the IXM system and blowing air from left to right
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through the IXM with a portable fan; internal temperature was monitored and recorded at
initiation and termination of each imaging protocol using a digital thermometer. In
accordance with National Institutes of Health (NIH) guidelines (National Institutes of
Health), 72-hpf embryos were then euthanized by placing the plate at 4°C for 30 minutes.
DATA EXTRACTION. Custom journal scripts for extraction of heart rate,
circulation, pericardial area, body length, and intersegmental vessel area data were
developed using MetaXpress® 4.0.0.24 software (Molecular Devices, Sunnyvale, CA).
Prior to data extraction, stream acquisitions within each well were inspected within
MetaXpress to assess embryo orientation and survival. Coagulated embryos or developed
embryos lacking a heartbeat were considered dead. Using these survival criteria, only
hatched and alive embryos positioned in right or left lateral recumbency were analyzed.
Interactive semi-automated journal scripts were used to isolate regions of interest and
quantify heart rate, circulation, pericardial area, and intersegmental vessel area, whereas a
fully automated journal script was used to quantify body length. Examples of raw and
analyzed images of control zebrafish for each endpoint are provided in Figure 3.2.
Additional details of the data extraction and analysis process are provided in Yozzo et al.
(2013b).

3.2.4 STATISTICAL ANALYSES
All statistical procedures were performed using SPSS Statistics 19.0 (Chicago,
IL). A general linear model (GLM) analysis of variance (ANOVA) (α = 0.05) was used
for all data, as these data did not meet the equal variance assumption for non-GLM
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ANOVAs. Pair-wise Tukey-based multiple comparisons of least square means were
performed to identify significant treatment-related effects.

3.3 RESULTS
3.3.1 OPTIMIZATION OF MS-222-BASED ANESTHESIA
As high MS-222 concentrations are known to adversely impact cardiac function
within zebrafish embryos (Burns et al., 2005), we first determined the lowest MS-222
concentration that fully anesthetized hatched 72-hpf embryos in the absence of significant
effects on heart rate. We exposed 72-hpf zebrafish to 50-300 mg/L MS-222 for 30
minutes, and then acquired and analyzed images for heart rate as described in Figure 3.1.
As 50 mg/L MS-222 was insufficient to fully anesthetize hatched 72-hpf embryos, MS222-induced effects on heart rate were only analyzed within 100-300 mg/L MS-222
treatment groups. Although percent survival was similar across all MS-222
concentrations (82-96%), there was a concentration-dependent decrease in sample size
(Figure 3.3A) and percent of successfully imaged embryos used for analysis of heart rate
(Table 3.1) – an effect that was largely a result of a concentration-dependent increase in
the percentage of embryos with orientation in dorsal recumbency.
While mean heart rates were significantly different across all concentrations
tested (Figure 3.3A), these minor differences were a result of high sample sizes, minimal
variation, and, as a result, high statistical power. Although mean heart rates across all
MS-222 concentrations tested were similar to heart rates of non-anesthetized 72-hpf
zebrafish analyzed at 28°C (Burns et al., 2005), we selected 100 mg/L MS-222 for all
subsequent HCS assays since this concentration (1) represented the lowest concentration
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necessary to fully anesthetize hatched 72-hpf embryos and (2) yielded the highest percent
of successfully imaged embryos (Table 3.1). Using this MS-222 concentration, we then
assessed heart rate every 12 minutes over a 132-minute image acquisition period
(following an initial immersion for 30 minutes), but found no significant effects on heart
rate across all time-points analyzed (Figure 3.3B). Therefore, these data demonstrated
that prolonged immersion of hatched 72-hpf embryos in 100 mg/L MS-222 provided full
anesthetization and high imaging success rates in the absence of significant effects on
heart rate over time.

3.3.2 ASSESSMENT OF BACKGROUND VARIABILITY
To evaluate background variability, we imaged four control plates containing
embryos incubated in EM from 5-72 hpf, and then immersed in 100 mg/L MS-222 for 30
minutes prior to imaging. Heart rate, circulation, pericardial area, body length, and
intersegmental vessel area were analyzed for each control plate using the parameters
described in Yozzo et al. (2013b). Percent survival and image success of hatched
embryos ranged from 93-99% and 42-74%, respectively (Table 3.2). Although
intersegmental vessel area and circulation data were variable, body length, pericardial
area, and heart rates were relatively consistent within and across plates (Figure 3.4).
Based on these data, we concluded that control performance within this HCS assay was
acceptable based on sample sizes ranging from 150 to 272 imaged embryos per plate.
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3.3.3 CHEMICAL SCREENING
Using protocols described in Yozzo et al. (2013b), 10 chemicals (Table A.1) were
screened to evaluate the potential for targeted effects on the cardiovascular system. This
sub-set of chemicals was selected in order to represent a range of chemical classes and
mechanisms of action. Based on a published list of known classes of cardiovascular
toxicants (Casarett et al., 2008; Kleinstreuer et al., 2011), nicotine, pyridaben, CL-4AS-1,
17β-estradiol, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and genistein were
hypothesized to be ‘positive’ within our assay, whereas endosulfan, paraoxon,
cypermethrin, and imidacloprid were hypothesized to be ‘negative’ within our assay.
Decision criteria for survival (>70% survival) and body length (<10% decrease relative to
vehicle controls) were developed based on performance within our control plates (Table
3.2 and Figure 3.4) as well as existing OECD test guidelines (http://www.oecdilibrary.org/content/package/chem_guide_pkg-en) for fish early life-stage toxicity
(OECD TG 210) and rodent chronic toxicity (OECD TG 452) to (1) minimize Type I and
II errors and reliably identify treatment-related effects and (2) focus our analyses on
targeted impacts on the cardiovascular system in the absence of significant effects on
embryonic growth (Figure 3.5). Based on the highest chemical concentration meeting
both criteria, we then performed a cluster analysis using QCanvas 1.2
(http://compbio.sookmyung.ac.kr/~qcanvas/) (Figure 3.6A). Pyridaben was the most
potent chemical to affect survival, as 0.78 µM was the highest concentration analyzed
due to 0% survival at higher concentrations. In addition, TCDD exposure resulted in the
most potent effects on body length even though survival was >70% at all concentrations
screened (1.51x10-4-0.155 µM). Importantly, 0.155 µM TCDD was the highest
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concentration tested since we were limited by the concentration of DMSO stock solution
purchased from Cambridge Isotope Laboratories; therefore, exposure to TCDD
concentrations >0.155 µM would likely have resulted in <70% survival. On the contrary,
imidacloprid and nicotine were the least potent chemicals and did not affect body length
nor survival across all concentrations tested (0.05 – 50 µM).
To determine targeted effects on the cardiovascular system, heart rate, circulation,
pericardial area, and intersegmental vessel area were assessed within treatment groups
with >70% survival and/or <10% decrease in body length relative to vehicle controls.
Out of 10 chemicals screened, TCDD and paraoxon were the only chemicals to result in a
significant concentration-dependent effect on one or more endpoints analyzed within
treatment groups meeting both analysis criteria (Figure 3.6B). Mean body length was
>10% lower than vehicle controls for paraoxon and TCDD concentrations higher than
0.78 and 0.004 µM, respectively. Therefore, these concentrations were the highest
concentrations analyzed for all endpoints. TCDD significantly decreased (p<0.05) arterial
circulation at the highest concentration analyzed (0.004 µM), and significantly increased
(p<0.05) pericardial area at all concentrations analyzed (1.51x10-4-0.004 µM) without
significantly affecting venous circulation, heart rate, and intersegmental vessel area. On
the other hand, paraoxon significantly decreased heart rate (p<0.05) at all concentrations
tested (0.05-50 µM) in the absence of effects on any other endpoints.

3.4 DISCUSSION
Although previous HCS assays using zebrafish have examined drug-induced heart
malformations and impacts on cardiac function (Burns et al., 2005; Padilla et al., 2012;
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Spomer et al., 2012; Tran et al., 2007; Wen et al., 2012), to our knowledge this is the first
HCS assay to provide a more comprehensive platform for quantifying body length, heart
rate, pericardial area, circulation, and intersegmental vessel area within the same embryo
– an advance that will, in the long-term, decrease the amount of time, zebrafish embryos,
and high-purity reference material needed for screening and identification of chemicals
impacting cardiovascular function. Using 384-well format, we were also able to increase
sample size (32 per treatment) and examine a broad concentration-response (vehicle
control and 11 chemical concentrations per plate). While we are not the first to use 384well plates, the majority of HCS assays using zebrafish rely on 96-well plates or low
sample sizes per treatment if using 384-well plates (Padilla et al., 2012; Spomer et al.,
2012; Tran et al., 2007). To reduce the potential for adverse side effects of anesthetizing
with MS-222, we attempted to immobilize hatched embryos by pre-exposing to light as
suggested in Burns et al. (2005); however, these attempts were unsuccessful, precluding
the possibility of eliminating MS-222-based anesthetization. Nonetheless,
anesthetization of embryos using MS-222 did not affect heart rate over time (Figure 3.3),
and heart rates in this study were similar to heart rates of non-anesthetized, 72-hpf
zebrafish embryos incubated at the same temperature (Burns et al., 2005). After analysis
of control plates demonstrated the assay was reliable, we then screened 10 chemicals and
determined that only TCDD and paraoxon exhibited a concentration-dependent effect on
cardiovascular function in the absence of effects on body length.
Using the highest concentration meeting body length and survival criteria (Figure
3.6A), we found that chemicals were clustered by site of action, suggesting that, within
384-well plates used for this assay, the magnitude of toxicity for chemicals with a
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common site of action is similar within zebrafish embryos. However, when we clustered
chemicals based on targeted effects to the cardiovascular system (Figure 3.6B), we found
that only two out of 10 chemicals – TCDD and paraoxon – affected the cardiovascular
system in a concentration-dependent manner, suggesting that, despite differences in
potency based on gross malformations, this assay has the potential to identify
cardiovascular toxicants.
Eight of the 10 chemicals screened did not adversely impact the cardiovascular
system using this assay, including five chemicals we initially hypothesized to be
‘positive’. For each chemical tested, a range of 11 concentrations based on two-fold serial
dilutions was used to increase the probability of capturing concentration-response curves
for survival, body length, and cardiovascular-specific endpoints. With the exception of
nicotine and imidacloprid (both of which were non-toxic up to 50 µM, the highest
concentration tested), all chemicals screened either decreased survival and/or body
length, suggesting that a negative finding was not a result of minimal uptake into
developing embryos due to high rates of chemical absorption to microplate wells or low
rates of chemical transport across the chorion. Rather, our negative findings for
chemicals hypothesized to be ‘positive’ for cardiovascular toxicity may be due to
differences in life stages (embryos vs. adults), experimental systems (whole animals vs.
cell lines), taxa (fish vs. rodents), exposure routes (aqueous vs. non-aqueous exposure),
and/or absence of chemical-specific sites of action within zebrafish. Since exposure to
nicotine and imidacloprid did not affect any of the endpoints evaluated within our assay,
these negative findings may have been due to limited embryonic uptake and/or low
sensitivity to acetylcholine receptor (AChR) activation during this stage of development.
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Nonetheless, these negative results further support the conclusion that – despite chemical
potency based on apical endpoints such as survival and body length – this assay has the
potential to identify chemicals that target cardiovascular function.
Within zebrafish embryos, TCDD is known to cause severe heart malformations
such as altered looping and reduced blood flow by activating the aryl hydrocarbon
receptor (AHR) (Antkiewicz et al., 2005; Carney et al., 2006; McGee et al., 2013).
Similarly, in our HCS assay TCDD significantly decreased arterial circulation and
increased pericardial area – an endpoint associated with incomplete cardiac looping –
without significantly affecting venous circulation, heart rate, and intersegmental vessel
area. While paraoxon is a known acetylcholinesterase (AChE) inhibitor and is often
associated with developmental neurotoxicity (Teixido et al., 2013; Yozzo et al., 2013a),
in our HCS assay paraoxon significantly decreased heart rate at all concentrations tested
in the absence of effects on any other endpoints. Therefore, this paraoxon-induced effect
on heart rate may have been undetected within cell-based systems, suggesting that
targeted HCS assays using intact embryos provide an opportunity to reveal unexpected
chemical MOAs.
In summary, compared to existing zebrafish-based assays, this HCS assay
provides a comprehensive discovery platform with sufficient power, replication, and
exposure concentrations to screen and identify potential cardiovascular toxicants. While
mechanisms of toxicity were not investigated within this study, in the future this HCS
assay can be readily coupled with reverse genetics approaches to identify the potential
role of xenobiotic receptors in chemically-induced effects on cardiovascular development
within zebrafish embryos. Therefore, over the long-term, we envision that this HCS assay
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will significantly increase the rate of screening and prioritizing chemicals for hypothesisdriven MOA research as well as uncover mechanisms of cardiovascular toxicity for
understudied high-production volume chemicals currently regulated under REACH and
TSCA.
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Table 3.1: Image success rates for analysis of heart rate within control 72-hpf zebrafish
embryos following a 30-minute immersion within 100-300 mg/L MS-222. The
percentage of embryos that were hatched and alive was relative to an initial sample size
of 384 embryos per MS-222 concentration, whereas the percentage of embryos that were
analyzed was relative to the number of hatched and alive embryos.
Table 3.1: Image success rates for analysis of heart rate within control 72-hpf zebrafish embryos following a 30-minute immersion within 100-300 mg/L MS-222.

MS-222
(mg/L)
100
150
200
250
300

Live + Hatched
Heart Rate
Total Total Analyzed Analyzed
(#)
(%)
(#)
(%)
352
91.7
258
73.3
319
83.1
204
63.9
370
96.4
197
53.2
332
86.5
172
51.8
315
82.0
123
39.0
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Table 3.2: Image success rates for analysis of all endpoints within control 72-hpf zebrafish embryos across four independent plates
containing an initial sample size of 384 embryos per plate. The percentage of embryos that were hatched and alive was relative to an
initial sample size of 384 embryos per MS-222 concentration, whereas the percentage of embryos that were analyzed was relative to
the number of hatched and alive embryos. Across all five endpoints, variation in the percentage of embryos analyzed was primarily
due to hatched embryos with orientation in dorsal rather than lateral recumbency.

Live +
Hatched

Length

Heart Rate

Pericardial Area

Intersegmental
Vessel Area

Circulation
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Control
Plate

Total
(#)

Total
(%)

Analyzed
(#)

Analyzed
(%)

Analyzed
(#)

Analyzed
(%)

Analyzed
(#)

Analyzed
(%)

Analyzed
(#)

Analyzed
(%)

Analyzed
(#)

Analyzed
(%)

1

369

96.1

259

70.2

257

69.6

272

73.7

253

68.6

244

66.1

2

357

93

244

68.3

244

68.3

246

68.9

228

63.9

229

64.1

3

361

94

189

52.4

189

52.4

186

51.5

167

46.3

150

41.6

4

380

99

229

60.3

229

60.3

229

60.3

212

55.8

200

52.6

Figure 7.1: Flow diagram summarizing the exposure setup, image acquisition, and endpoints
for the 384-well-based HCS assay.

Figure 3.1: Flow diagram summarizing the exposure setup, image acquisition, and
endpoints for the 384-well-based HCS assay. Using automated image acquisition
protocols and parameters optimized for our ImageXpress® Micro Widefield HighContent Screening System, each fli1:egfp embryo was imaged to analyze the following
endpoints: heart rate; circulation; pericardial area; body length; and intersegmental vessel
area.
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Figure 8:
Representat
ive raw and
analyzed
images of
vehicletreated
zebrafish
embryos
used to
determine
body length,
heart rate,
intersegmen
tal vessel
area,
pericardial
area, and
circulation

Figure 3.2: Representative raw (left) and analyzed (right) images of vehicle-treated
zebrafish embryos used to determine A) body length; B) heart rate; C) intersegmental
vessel area; D) pericardial area; and E) circulation. Lines, circles, and boxes within
analyzed images denote areas of measurement for each endpoint. For circulation, the
green, blue, and purple lines (black arrows) within the analyzed image denote lines used
to quantify arterial circulation, venous circulation, and background intensity,
respectively.
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Figure 9: Mean (± SD) heart rate of 72-hpf fli1:egfp zebrafish embryos following a 30-min immersion within 100-300 mg/L MS-222 or or
every 12 minutes over a 132-minute image acquisition period following initial immersion within 100 mg/L MS-222 (N=22) for 30 minutes

Figure 3.3: Mean heart rate (± SD) of 72-hpf fli1:egfp zebrafish embryos following a 30minute immersion within 100-300 mg/L MS-222 (A) or every 12 minutes over a 132minute image acquisition period following initial immersion within 100 mg/L MS-222
(N=22) for 30 minutes (B). In panel A, treatments that do not share the same letter are
significantly different (p < 0.05) from each other. In panel B, no significant differences
were detected across all time points.

60

Figure 10: Mean body length (± SD), intersegmental vessel area (± SD), pericardial area (± SD), heart rate (± SD), arterial circulation (± SD), and venous circulation (± SD) across
four independent control plates consisting of 384 initial embryos per plate.

Figure 3.4: Mean body length (± SD) (A), intersegmental vessel area (± SD) (B),
pericardial area (± SD) (C), heart rate (± SD) (D), arterial circulation (± SD) (E), and
venous circulation (± SD) (F) across four independent control plates consisting of 384
initial embryos per plate. N = final number of embryos analyzed per plate. Treatments
that do not share the same letter are significantly different (p < 0.05) from each other.
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Figure 3.5: Decision tree for evaluation of assay performance and validity during exposure setup (Day 0), image acquisition (Day 3),
and data extraction/analysis (Days 4-5). Criteria for survival (>70% survival) and body length (<10% decrease relative to vehicle
controls) were developed to (1) minimize Type I and II errors and reliably identify treatment-related effects and (2) focus our analyses
on targeted impacts on the cardiovascular system in the absence of significant effects on embryonic growth.
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Figure 12: Hierarchical cluster of chemical screening data based on the highest concentration meeting survival and body length criteria and
presence or absence of a concentration-dependent response on the cardiovascular system at non-teratogenic concentrations

Figure 3.6: Hierarchical cluster of chemical screening data based on the highest
concentration meeting survival and body length criteria (A) and presence or absence of a
concentration-dependent response on the cardiovascular system at non-teratogenic
concentrations (B). The predicted logP value for each chemical was determined using an
interactive logP predictor tool at www.molinspiration.com/cgi-bin/properties. Supporting
figures for all chemical screening assays as well as chemical structures are provided in
Yozzo et al. (2013b).
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CHAPTER 4
CONCLUSIONS AND FUTURE RESEARCH
The first study (Chapter 2) demonstrated that quantitative AOPs are difficult to
develop even during the same developmental stage (embryogenesis) within the same
organism (zebrafish). In fact, after exposure to non-teratogenic concentrations of
paraoxon, an adverse outcome occurring at 26 hpf did not correspond to an adverse
outcome at 96 hpf. Currently, there is an interest in developing qualitative AOPs, where
data is collated from the literature to predict toxic effects at other levels of biological
organization; however, this method may be problematic. The initiating event may be the
same across these multiple levels of biological organization but may not lead to an
adverse outcome at the higher levels. For example, embryos developed normally even
when AChE was significantly inhibited, thus the initiating event (AChE inhibition) did
not necessarily cause an adverse outcome at a higher level of organization. Additionally,
in this study, AChE was inhibited after exposure to paraoxon; however, even in the
presence of minimal AChE activity, the frequency of spontaneous tail contractions
(adverse outcome) was significantly higher within 26-hpf embryos exposed to paraoxon.
This suggests that AChE inhibition is not likely the initiating event causing the adverse
outcome of increased frequency of spontaneous tail contractions, and other initiating
events may play a role.
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Future studies should be conducted to investigate initiating events that may lead
to an increase in spontaneous tail contractions. Muscarinic and nicotinic AChRs are
present within primary motor neuron axons (Behra et al., 2002); thus paraoxon-induced
activation of these receptors can be examined. In a preliminary study, we unsuccessfully
attempted to increase spontaneous tail contractions by exposing zebrafish embryos to
acetylcholine. However, after further review, the concentrations of acetylcholine we used
were much lower than those suggested to activate these receptors (Thomas et al., 2009).
Future studies could be conducted using higher concentrations of acetylcholine as a
positive control, and then co-exposing the embryos to paraoxon and either scopolamine
hydrobromide (a muscarinic antagonist) or mecamylamine hydrochloride (a nicotinic
antagonist) to determine if exposure to paraoxon activates either receptor.
Additional future studies could also be conducted to explore non-cholinergic
pathways and gap junction development. Gap junctions play an important role in linking
spinal cord neurons and propagating spontaneous electrical current-driven depolarization
within the motor network (Saint-Amant and Drapeau, 2001); thus, the adverse outcome
of increased spontaneous tail contractions may be mediated through improper gap
junction development. Finally, the development of primary motoneurons could be
examined as well using immunohistochemistry techniques; we only examined secondary
motoneurons and found no effect after exposure to paraoxon. Since there was an adverse
outcome during the window of development in which primary motoneurons are present,
there may be an effect on development of these motoneurons.
The second study (Chapter 3) demonstrated that HTS/HCS methods can been
used to 1) screen and prioritize chemicals for further testing in other animal models; 2)
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help fill in the gaps of hypothesized AOPs; and 3) help develop new AOPs. For example,
in the current chemical screen, paraoxon, a known AChE inhibitor that is often associated
with developmental neurotoxicity (Teixido et al., 2013; Yozzo et al., 2013a), was chosen
as a “negative” reference chemical and not expected to affect cardiovascular
development. Conversely, exposure to non-teratogenic concentrations of paraoxon
significantly decreased heart rate at all concentrations tested in the absence of effects on
any other endpoints. Nonetheless, these results can help support and introduce a
cardiovascular AOP for paraoxon in addition to those developed for the nervous system
such as the AOP described in Figure 2.6. In fact, hypothesis-driven, low-throughput
studies could be conducted to examine the MOA of paraoxon as well as TCDD, the only
other chemical to screen “positive” for cardiotoxicity, more closely. These follow-up
studies can be used to fill in the gaps of key initiating events within AOPs.
Even though the HCS assay described in Chapter 3 was successful in identifying
chemicals that affect cardiovascular development within zebrafish embryos, there were a
few limitations of the assay. First, the data extraction was more time consuming that we
anticipated, making this assay more of a medium-throughput assay compared to other
assays that can test hundreds of chemicals with a weeks time. However, this assay was
able to rapidly produce more data compared to manual imaging procedures using a
microscope or using immunohistochemistry methods and a confocal microscope. Second,
due to using fluorescence as a way to quantify intersegmental vessel area, we were
unable to screen chemicals that autofluoresce due to an increase in the background
intensity within wells, creating a concentration-dependent increase in fluorescence that
was not directly related to an increase in intersegmental vessel area. Lastly, we were only
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able to detect a difference in circulation when there was a reduction in blood cells and not
when the blood flow was slower. Due to complications at higher magnifications, 4X
magnification was the highest we could use to image circulation. However, at this
magnification, the blood cells were not large enough to image individual cells, so we
were unable to track blood cells over time to determine the velocity of circulation. After
manually viewing each chemical screen, TCDD was the only compound to affect
circulation, so we used FFT magnitude as a method for quantifying changes in
circulation. Even with these few limitations, this assay can be used to screen chemicals
and successfully identify cardiotoxicants.
Overall, by relying on zebrafish-based developmental toxicity assays, we were
able to develop: (1) an AOP describing the potential key initiating events that lead to the
adverse outcome of increased spontaneous tail contractions when exposed to paraoxon;
and (2) a high-content imaging assay that can be used to screen chemicals and
successfully identify cardiotoxicants. Furthermore, this study highlights the challenges of
developing quantitative AOPs. Nonetheless, qualitative AOPs can be used to help
prioritize which chemicals should be screened within HCS. The results of these chemical
screens can help fill gaps within current AOPs as well as facilitate the development of
new AOPs. Chemicals can then prioritized for further testing within conventional animal
models that can help understand the effects of these chemicals to the human population.
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APPENDIX A: SUPPLEMENTAL TABLE
Table A.1: Chemical name, chemical formula, CAS registry number, vendor, and purity
of all chemicals screened.
Table 2: Chemical name, chemical formula, CAS registry number, vendor, and purity of all chemicals screened

Chemical
Name
CL-4AS-1
Cypermethrin
Endosulfan
17B-Estradiol

Chemical
Formula
C26H33ClN2O2
C22H19Cl2NO3
C9H6Cl6O3S
C18H24O2

Genistein
Imidacloprid
Nicotine
Paraoxon
Pyridaben
2,3,7,8-TCDD

C15H10O5
C9H10ClN5O2
C10H14N2
C10H14NO6P
C19H25ClN2OS
C12H4Cl4O2

CAS #
188589-66-4
52315-07-8
115-29-7
50-28-2
446-72-0
138261-41-3
54-11-5
311-45-5
96489-71-3
1746-01-6
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Vendor
Tocris Bioscience
ChemService Inc.
ChemService Inc.
Tocris Bioscience
Tocris Bioscience
ChemService Inc.
ChemService Inc.
ChemService Inc.
ChemService Inc.
Cambridge Isotope Libraries, Inc.

Purity
(%)
>99.7
99.0
99.0
99.0
>98.0
99.5
99.2
97.5
99.5
99.2

